secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-09-15T23:59:59+00:00
Accession:  0001493152-25-013459
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA announces positive preclinical PTSD data for Ketamir-2 in rat model
------------------------------------------------------------------------

- Ketamir-2 reversed stress-induced avoidance, anxiety, and despair in rats after 5 daily oral doses.
- Results from Single Prolonged Stress model showed behavior normalized to non-stressed animal levels.
- Ketamir-2 is also in a Phase 1 trial for neuropathic pain with a favorable safety profile to date.
- DEA concluded Ketamir-2 is not a controlled substance under the Controlled Substances Act.
- A larger follow-on PTSD study in animals is ongoing; results support further development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315225013459/0001493152-25-013459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315225013459/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-013459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer